Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]

Blog Article

Buhl R, Banerji D.Int J Chron Obstruct Pulmon Dis.2012;7:729–741.On page 737 in the first paragraph of the "Safety" section, the final sentence "Serious adverse events fr9352 occurred with a slightly lower frequency in the glycopyrronium treatment group (11%) compared with placebo (13%) and the tiotropium group (15%, Table 3).

32,33" should read "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (10%) compared vive night splint with placebo (13%) and the tiotropium group (15%, Table 3).32,33"Read the original article .